Are you please able to post how you come to this conclusion with your thoughts that in the lower albuminuria group, their levels went up - as in your maths working out? I’m genuinely interested.
It was noted in the investor call that patients in this lower cohort had an average of 14% reduction in albuminuria on treatment, but a confounding factor of 12% reduction while on placebo, which is where this 2% comes in & what they will be looking at in terms of legacy effect on placebo & also concomitant medication (particularly SGLT2s).
Someone actually asked that question in the investor call - did the albuminuria levels go up in the lower baseline albuminuria group (<500mg/g) and Professor Packham said NO.
I’m sorry to see you go RL, I have been enjoying your posts.
DXB Price at posting:
24.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)